CEP-37251
C37251/1080
Phase 1 small_molecule terminated
Quick answer
CEP-37251 for Bone Loss is a Phase 1 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Pharma GmbH
- Indication
- Bone Loss
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- terminated